Tivanisiran sodium is a siRNA used for the study of dry eye disease. Tivanisiran sodium was designed to silence transient receptor potential vanilloid 1 (TRPV1) mRNA.
References:
[1]. Anne-Marie Bleau, et al. Development of tivanisiran, a topical siRNA designed to
[2]. Javier Moreno-Montañés, et al. Tivanisiran, a novel siRNA for the treatment of dry eye disease. Expert Opin Investig Drugs. 2018 Apr;27(4):421-426.
















